SCHEMBL325045

SCHEMBL325045

Cn1ccc(COC(=O)N2C=Cc3ccccc3C2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.38
CHRM2 P08172 1/20 0.37
CHRM4 P08173 1/20 0.37
CHRM1 P11229 1/20 0.37
CHRM3 P20309 1/20 0.37
HDAC3 O15379 1/20 0.36
TSHR P16473 1/20 0.34
NOTUM Q6P988 1/20 0.34
GRM2 Q14416 1/20 0.34
JAK2 O60674 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ALOX5AP P20292 2/20 0.33
JMJD6 Q6NYC1 1/20 0.32
KDM1A O60341 1/20 0.32
P2RX4 Q99571 1/20 0.32
PRMT5 O14744 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14893014 0.82 ALDH1A1 (0.36) HDAC3TSHRKDM4EALDH1A1LMNA
SCHEMBL15057230 0.80 NPC1 (0.43) HDAC3TSHRKDM4EALDH1A1LMNA
SCHEMBL15056293 0.80 DPP4 (0.41) HDAC3PRMT5WDR77OPRM1
SCHEMBL15056964 0.79 HDAC3 (0.41) NAMPTHDAC3TSHRKDM4EALDH1A1
SCHEMBL29493251 0.79 HDAC3 (0.41) NAMPTHDAC3TSHRKDM4EALDH1A1
SCHEMBL324037 0.79 MAPT (0.40) KDM4EALDH1A1LMNANPC1
SCHEMBL324299 0.78 P2RX4 (0.52) ALDH1A1SMN1; SMN2P2RX4NPC1
SCHEMBL324898 0.78 PTGDR2 (0.39) HDAC3TSHRGRM2ALDH1A1LMNA
SCHEMBL324968 0.78 ALDH1A1 (0.44) NAMPTTSHRKDM4EALDH1A1HTT
SCHEMBL325482 0.77 PTGDR2 (0.37) HDAC3LMNAP2RX4PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575158-B2 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators ACTELION PHARMACEUTICALS LTD. (CH) 2013-11-05 US disclosed
EP-2590944-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-05-15 EP disclosed
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-05-02 US disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGER1, PTGDR, PTGDR2 NAMPT 2828/4885CHRM2 220/4885CHRM4 581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.